Kefir metabolites in a fly model for Alzheimer’s disease

Abstract Alzheimer’s Disease (AD) is the most common cause of dementia among elderly individuals worldwide, leading to a strong motor-cognitive decline and consequent emotional distress and codependence. It is traditionally characterized by amyloidogenic pathway formation of senile plaques, and rece...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Letícia Leandro Batista, Serena Mares Malta, Heitor Cappato Guerra Silva, Luiza Diniz Ferreira Borges, Lays Oliveira Rocha, Jéssica Regina da Silva, Tamiris Sabrina Rodrigues, Gabriela Venturini, Kallyandra Padilha, Alexandre da Costa Pereira, Foued Salmen Espindola, Carlos Ueira-Vieira
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/860973d16bb74a8eafd5b028be31c301
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:860973d16bb74a8eafd5b028be31c301
record_format	dspace
spelling	oai:doaj.org-article:860973d16bb74a8eafd5b028be31c3012021-12-02T14:49:24ZKefir metabolites in a fly model for Alzheimer’s disease10.1038/s41598-021-90749-82045-2322https://doaj.org/article/860973d16bb74a8eafd5b028be31c3012021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90749-8https://doaj.org/toc/2045-2322Abstract Alzheimer’s Disease (AD) is the most common cause of dementia among elderly individuals worldwide, leading to a strong motor-cognitive decline and consequent emotional distress and codependence. It is traditionally characterized by amyloidogenic pathway formation of senile plaques, and recent studies indicate that dysbiosis is also an important factor in AD’s pathology. To overcome dysbiosis, probiotics—as kefir—have shown to be a great therapeutic alternative for Alzheimer’s disease. In this present work, we explored kefir as a probiotic and a metabolite source as a modulator of microbiome and amyloidogenic pathway, using a Drosophila melanogaster model for AD (AD-like flies). Kefir microbiota composition was determined through 16S rRNA sequencing, and the metabolome of each fraction (hexane, dichloromethane, ethyl acetate, and n-butanol) was investigated. After treatment, flies had their survival, climbing ability, and vacuolar lesions accessed. Kefir and fraction treated flies improved their climbing ability survival rate and neurodegeneration index. In conclusion, we show that kefir in natura, as well as its fractions may be promising therapeutic source against AD, modulating amyloidogenic related pathways.Letícia Leandro BatistaSerena Mares MaltaHeitor Cappato Guerra SilvaLuiza Diniz Ferreira BorgesLays Oliveira RochaJéssica Regina da SilvaTamiris Sabrina RodriguesGabriela VenturiniKallyandra PadilhaAlexandre da Costa PereiraFoued Salmen EspindolaCarlos Ueira-VieiraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Letícia Leandro Batista Serena Mares Malta Heitor Cappato Guerra Silva Luiza Diniz Ferreira Borges Lays Oliveira Rocha Jéssica Regina da Silva Tamiris Sabrina Rodrigues Gabriela Venturini Kallyandra Padilha Alexandre da Costa Pereira Foued Salmen Espindola Carlos Ueira-Vieira Kefir metabolites in a fly model for Alzheimer’s disease
description	Abstract Alzheimer’s Disease (AD) is the most common cause of dementia among elderly individuals worldwide, leading to a strong motor-cognitive decline and consequent emotional distress and codependence. It is traditionally characterized by amyloidogenic pathway formation of senile plaques, and recent studies indicate that dysbiosis is also an important factor in AD’s pathology. To overcome dysbiosis, probiotics—as kefir—have shown to be a great therapeutic alternative for Alzheimer’s disease. In this present work, we explored kefir as a probiotic and a metabolite source as a modulator of microbiome and amyloidogenic pathway, using a Drosophila melanogaster model for AD (AD-like flies). Kefir microbiota composition was determined through 16S rRNA sequencing, and the metabolome of each fraction (hexane, dichloromethane, ethyl acetate, and n-butanol) was investigated. After treatment, flies had their survival, climbing ability, and vacuolar lesions accessed. Kefir and fraction treated flies improved their climbing ability survival rate and neurodegeneration index. In conclusion, we show that kefir in natura, as well as its fractions may be promising therapeutic source against AD, modulating amyloidogenic related pathways.
format	article
author	Letícia Leandro Batista Serena Mares Malta Heitor Cappato Guerra Silva Luiza Diniz Ferreira Borges Lays Oliveira Rocha Jéssica Regina da Silva Tamiris Sabrina Rodrigues Gabriela Venturini Kallyandra Padilha Alexandre da Costa Pereira Foued Salmen Espindola Carlos Ueira-Vieira
author_facet	Letícia Leandro Batista Serena Mares Malta Heitor Cappato Guerra Silva Luiza Diniz Ferreira Borges Lays Oliveira Rocha Jéssica Regina da Silva Tamiris Sabrina Rodrigues Gabriela Venturini Kallyandra Padilha Alexandre da Costa Pereira Foued Salmen Espindola Carlos Ueira-Vieira
author_sort	Letícia Leandro Batista
title	Kefir metabolites in a fly model for Alzheimer’s disease
title_short	Kefir metabolites in a fly model for Alzheimer’s disease
title_full	Kefir metabolites in a fly model for Alzheimer’s disease
title_fullStr	Kefir metabolites in a fly model for Alzheimer’s disease
title_full_unstemmed	Kefir metabolites in a fly model for Alzheimer’s disease
title_sort	kefir metabolites in a fly model for alzheimer’s disease
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/860973d16bb74a8eafd5b028be31c301
work_keys_str_mv	AT leticialeandrobatista kefirmetabolitesinaflymodelforalzheimersdisease AT serenamaresmalta kefirmetabolitesinaflymodelforalzheimersdisease AT heitorcappatoguerrasilva kefirmetabolitesinaflymodelforalzheimersdisease AT luizadinizferreiraborges kefirmetabolitesinaflymodelforalzheimersdisease AT laysoliveirarocha kefirmetabolitesinaflymodelforalzheimersdisease AT jessicareginadasilva kefirmetabolitesinaflymodelforalzheimersdisease AT tamirissabrinarodrigues kefirmetabolitesinaflymodelforalzheimersdisease AT gabrielaventurini kefirmetabolitesinaflymodelforalzheimersdisease AT kallyandrapadilha kefirmetabolitesinaflymodelforalzheimersdisease AT alexandredacostapereira kefirmetabolitesinaflymodelforalzheimersdisease AT fouedsalmenespindola kefirmetabolitesinaflymodelforalzheimersdisease AT carlosueiravieira kefirmetabolitesinaflymodelforalzheimersdisease
_version_	1718389521537564672

Kefir metabolites in a fly model for Alzheimer’s disease

Ejemplares similares